Recombinant subunit vaccine elicits protection against goose haemorrhagic nephritis and enteritis.
Outbreaks of haemorrhagic nephritis and enteritis of geese (HNEG) have been reported in goose flocks in Hungary, Germany and France since 1969. HNEG is characterized by high morbidity and mortality rates in geese 3 to 10 weeks of age. The causative agent of HNEG is the goose haemorrhagic polyomavirus (GHPV), which has a circular double-stranded DNA genome encoding the structural proteins VP1, VP2 and VP3. In vitro culture of GHPV has been problematic, so the baculovirus system was used to construct a recombinant virus expressing the VP1 gene of GHPV under control of the polyhedrin promoter in Sf9 insect cells. The expression and the identity of recombinant goose polyomavirus VP1 in the crude Sf9 cell extracts were confirmed by mass spectrometry. Experimental oil-emulsion vaccines containing two different doses of antigen were prepared using this crude extract. Goslings were vaccinated either once at 1 day old or twice by boosting 18 days after the primary vaccination, and were challenged with a virulent polyomavirus isolate at 5 weeks of age. A single injection of either vaccine dose induced 95% protection against challenge. Using the booster vaccination regimen, 100% protection was achieved with either vaccine dose.